Swiss National Bank Has $7.38 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Swiss National Bank lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTKGet Rating) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 187,700 shares of the biopharmaceutical company’s stock after purchasing an additional 9,200 shares during the quarter. Swiss National Bank’s holdings in Cytokinetics were worth $7,375,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Mutual of America Capital Management LLC grew its stake in Cytokinetics by 5.5% in the 1st quarter. Mutual of America Capital Management LLC now owns 12,087 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 627 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in Cytokinetics by 9.1% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 75,013 shares of the biopharmaceutical company’s stock valued at $2,761,000 after buying an additional 6,275 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Cytokinetics by 7.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 19,834 shares of the biopharmaceutical company’s stock valued at $730,000 after buying an additional 1,419 shares during the last quarter. Victory Capital Management Inc. grew its stake in Cytokinetics by 166.2% in the 1st quarter. Victory Capital Management Inc. now owns 23,063 shares of the biopharmaceutical company’s stock valued at $920,000 after buying an additional 14,398 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its stake in Cytokinetics by 14.9% in the 1st quarter. Advisor Group Holdings Inc. now owns 5,930 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 767 shares during the last quarter.

Insider Transactions at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 21,500 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $51.88, for a total transaction of $1,115,420.00. Following the completion of the transaction, the executive vice president now directly owns 168,346 shares of the company’s stock, valued at approximately $8,733,790.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Robert Wong sold 2,100 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $40.68, for a total transaction of $85,428.00. Following the completion of the transaction, the chief accounting officer now directly owns 30,537 shares of the company’s stock, valued at approximately $1,242,245.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Fady Ibraham Malik sold 21,500 shares of the firm’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $51.88, for a total transaction of $1,115,420.00. Following the transaction, the executive vice president now directly owns 168,346 shares of the company’s stock, valued at $8,733,790.48. The disclosure for this sale can be found here. In the last three months, insiders sold 120,872 shares of company stock valued at $5,975,182. Company insiders own 5.00% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. StockNews.com lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Friday, November 4th. UBS Group assumed coverage on shares of Cytokinetics in a research note on Tuesday, October 11th. They issued a “buy” rating and a $80.00 target price on the stock. JMP Securities raised their target price on shares of Cytokinetics from $53.00 to $82.00 and gave the company a “market outperform” rating in a research note on Monday, October 3rd. Morgan Stanley raised their price target on shares of Cytokinetics from $11.00 to $15.00 in a research report on Friday, August 12th. Finally, Cantor Fitzgerald raised their price target on shares of Cytokinetics from $56.00 to $69.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $40.05 on Wednesday. The company’s fifty day moving average is $45.77 and its two-hundred day moving average is $45.08. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of -12.67 and a beta of 0.98. Cytokinetics, Incorporated has a 52-week low of $29.26 and a 52-week high of $55.80. The company has a debt-to-equity ratio of 1.77, a current ratio of 11.56 and a quick ratio of 11.56.

Cytokinetics Profile

(Get Rating)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Featured Stories

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTKGet Rating).

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.